We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, a... Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. Show more
FDA Approves Lilly's EBGLYSSβ’ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis PR Newswire INDIANAPOLIS, Sept. 13, 2024 EBGLYSS provides a...
Lilly expands manufacturing footprint in Ireland with $1.8 billion investment PR Newswire INDIANAPOLIS, Sept. 12, 2024 Company ups manufacturing investment in Limerick by $1 billion; unveils new...
With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes PR Newswire INDIANAPOLIS, Sept. 10, 2024 Detailed results...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -7.51 | -0.80730986294 | 930.25 | 939.86 | 902.3 | 3631065 | 917.30796501 | CS |
4 | -26.46 | -2.78761061947 | 949.2 | 972.48 | 893 | 2730498 | 926.67537337 | CS |
12 | 10.74 | 1.17763157895 | 912 | 972.53 | 747.55 | 3316702 | 888.78791619 | CS |
26 | 152.47 | 19.7943578226 | 770.27 | 972.53 | 718.3 | 2945026 | 845.71148916 | CS |
52 | 370.21 | 67.0026966862 | 552.53 | 972.53 | 516.57 | 3086038 | 738.77330327 | CS |
156 | 693.44 | 302.416048844 | 229.3 | 972.53 | 220.2 | 2995034 | 476.47468063 | CS |
260 | 806.74 | 695.465517241 | 116 | 972.53 | 101.36 | 3260518 | 335.99703279 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions